Clinical trials: Metastatic Neoplasm
SSTR-related Disease, Tumor
Somatostatin Receptor PET/CT in SSTR-Related Disease Patients
To evaluate the potential usefulness of 68Ga/18F-TATE/JR11/LM3 positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various SSTR-related disease patients.
- Conditions
- SSTR-related Disease, Tumor, Positron Emission Tomography, Metastasis
- Trial name
- NCT06690957
- Testing
- 68Ga/18F-TATE/JR11/LM3
- Where
- 3 sites in China
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Tianjin Medical University
Squamous Cell Carcinoma, Head And Neck
A Phase II Trial Evaluating WNT974 in Patients With Metastatic Head and Neck Squamous Cell Carcinoma
Given that up-regulation of the Wnt pathway has been identified as having a significant role in carcinogenesis in advanced head and neck squamous cell carcinoma, the investigator believes that inhibition of Porcupine via WNT974…
- Trial name
- NCT02649530
- Testing
- WNT974
- Where
- United States
- Sponsor
- University of Michigan Rogel Cancer Center
Solid Cancers
A Study of the Safety and Pharmacokinetics of GDC-0152, Administered Intravenously to Patients With Locally Advanced or Metastatic Malignancies
The study consists of two stages. In Stage 1, maximum tolerated dose (MTD) will be determined. In Stage 2, additional patients will be treated at the MTD of GDC-0152.
- Trial name
- NCT00977067
- Testing
- GDC-0152
- Volunteers
- 40 people
- Sponsor
- Genentech, Inc.
Metastatic Cancer, Radiation Toxicity
Melatonin and Radiation Therapy in Treating Patients With Brain Metastases
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs such as melatonin may make tumor cells more sensitive to radiation therapy and may protect normal cells from the side effects of radiation therapy.
- Conditions
- Metastatic Cancer, Radiation Toxicity, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00031967
- Testing
- therapeutic melatonin, radiation therapy
- Where
- 234 sites in United States, Canada
- Sponsor
- Radiation Therapy Oncology Group
Prostate Cancer Metastatic Castration-Resistant
A Study of KMV002 in Patients With mAPMR Prostate Cancer
This is a first-in-human (FIH) open-label, multicenter, dose-escalation and dose-expansion Phase I study of KMV002 in metastatic androgen pathway modulation-resistant (mAPMR) prostate cancer patients.
- Trial name
- NCT07866300
- Testing
- KMV002
- Where
- 2 sites in Australia
- Volunteers
- 24 people
- Sponsor
- Chimivac INC
Lung Cancer, Lung Cancer Metastatic
Feasibility Study of the RF Ablation Catheter to Ablate Lung Tumors
The feasibility of a RF ablation catheter to bronchoscopically ablate lung tumors, will be evaluated in patients already scheduled for surgical resection.
- Conditions
- Lung Cancer, Lung Cancer Metastatic, Lung Cancer, Non-small Cell
- Trial name
- NCT03272971
- Testing
- Radio-frequency Ablation
- Where
- China
- Volunteers
- 3 people
- Sponsor
- Broncus Medical Inc
Breast Cancer
Extended Treatment in Metastatic Breast Cancer With Eribulin
Decision-making for treatment of metastatic breast cancer after the second line of chemotherapy was limited by the lack of established predictive factors of benefit for further chemotherapy regimens.
- Trial name
- EXTER (NCT02769364)
- Where
- 21 sites in Spain
- Volunteers
- 45 people
- Sponsor
- Eisai Limited
Breast Cancer, Colorectal Cancer
Pharmacokinetic Study of Capecitabine in Elderly Cancer Patient (≥ 75 Years)
The aim of the study is to determine blood concentration evolution of capecitabine and its active metabolites, in elderly patient 75 years and more.
- Trial name
- capagec (NCT00812864)
- Testing
- Capecitabine
- Where
- France
- Volunteers
- 20 people
- Sponsor
- University Hospital, Limoges
Peritoneal Cancer, Peritoneal Metastases
The PIPAC-OPC7 Study: The Use of PET/CT Scans as a Method of Evaluation in Patients Treated With PIPAC, a Pilot Study.
The pilot study will investigate the use of repeated FDG-PET/CT scans in 16 patients with peritoneal metastasis originating from abdominal cancers treated with Pressurized Intraperitoneal Aerosol Chemotherapy.
- Conditions
- Peritoneal Cancer, Peritoneal Metastases, Peritoneal Carcinomatosis, Abdominal Cancer
- Trial name
- NCT06144853
- Testing
- scan
- Where
- Denmark
- Volunteers
- 34 people
- Sponsor
- Odense University Hospital
Metastatic Renal Cell Carcinoma
Non-Interventional Study (NIS) In Patients With Advanced And/Or Metastatic Renal Cell Carcinoma (mRCC) Treated With SUTENT®
Primary objective: to increase knowledge about safety, tolerability, quality of life and efficacy under conditions of routine use of SUTENT®.
- Trial name
- NCT00684645
- Testing
- SUTENT
- Where
- 20 sites in Czechia
- Volunteers
- 186 people
- Sponsor
- Pfizer
Primary Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma
Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas
This study is being conducted to evaluate the safety and efficacy of the combination of pemetrexed and zanubrutinib (called induction therapy) followed by zanubrutinib treatment alone (also called maintenance therapy) in people…
- Conditions
- Primary Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma, Relapsed Cancer, Refractory Cancer
- Trial name
- NCT05681195
- Testing
- Pemetrexed, Zanubrutinib, Autologous Stem Cell Transplant (ASCT)
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Baptist Health South Florida
Sarcoma
Anlotinib Hydrochloride Combined With Liposomal Doxorubicin in the Treatment of Locally Advanced or Metastatic Soft Tissue Sarcoma
The investigators explored the activity of anlotinib combined with Liposomal Doxorubicin in patients with Locally Advanced or Metastatic Soft Tissue Sarcoma
- Trial name
- ALTER-S001 (NCT03880695)
- Testing
- Anlotinib+ Liposomal Doxorubicin
- Where
- 8 sites in China
- Volunteers
- 48 people
- Sponsor
- Peking University People's Hospital
Non-Small Cell Lung Cancer With EGFR-mutated and PD-L1 Positive
A Phase 2 Study of ABSK043 Combined With Osimertinib
This is a phase 2, open-Label study to evaluate the efficacy and safety of ABSK043 Combined with Osimertinib in participants with EGFR-Mutated locally advanced or metastatic Non-Small Cell Lung Cancer
- Trial name
- NCT07710612
- Testing
- ABSK043 in combination with Osimertinib
- Where
- 7 sites in China
- Volunteers
- 72 people
- Sponsor
- Abbisko Therapeutics Co, Ltd
Leukemia
Combination Chemotherapy Plus PSC-833 in Treating Children With Refractory or Relapsed Acute Leukemia
Phase I trial to study the effectiveness of PSC-833 plus etoposide and mitoxantrone in treating children who have refractory or relapsed acute leukemia.
- Trial name
- NCT00002912
- Testing
- etoposide, mitoxantrone hydrochloride, valspodar
- Where
- 55 sites in United States, Australia and 1 more
- Volunteers
- 3 people
- Sponsor
- National Cancer Institute (NCI)
Hematological Malignancies, Leukemia
STA-5312 Administered on Alternate Weekdays Every Two Weeks to Patients With Hematologic Malignancies and Patients With Solid Tumors
The purpose of this study is to determine the safety, toxicity and patient tolerance of STA-5312 administered intravenously to patients with relapsed or refractory hematological malignancies and patients with solid tumors.
- Conditions
- Hematological Malignancies, Leukemia, Lymphoma, Metastatic or Unresectable Solid Tumors
- Trial name
- NCT00088101
- Testing
- STA-5312
- Where
- 8 sites in United States
- Volunteers
- 42 people
- Sponsor
- Synta Pharmaceuticals Corp.
Metastatic Renal Cell Carcinoma
Retrospective Analysis of Patients With Metastatic Renal Cell Carcinoma Treated With CABOzantinib
CABOGEN is a Observational, retrospective, multicenter study that will enroll patients with metastatic clear cell renal carcinoma (mccRCC) treated with cabozantinib after one or more previous lines of treatment that included…
- Trial name
- CABOGEN (NCT06548867)
- Testing
- Cabozantinib
- Where
- Italy
- Volunteers
- 80 people
- Sponsor
- Gruppo Oncologico Italiano di Ricerca Clinica
Single Patient Protocol: A Phase II Study Using the Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated Neoantigens in a Patient With Metastatic Cancer Plus the Administration of Pembrolizumab
Single Patient Expanded Access
- Trial name
- NCT04135092
- Testing
- Individual Patient TCR Transduced PBL, Cyclophosphamide, Fludarabine
- Sponsor
- National Institutes of Health Clinical Center (CC)
Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Cancer
Liquid Biopsy and Pancreas Cancer: Detection of AXL(+) CTCs (CTC-AXL-PANC)
In solid cancers, some more aggressive tumor cells actively detach from the primary lesion and then travel through the circulating compartment to reach distant organs and form micro-metastases.
- Conditions
- Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Cancer, Circulating Tumor Cell
- Trial name
- CTC-AXL-PANC (NCT05346536)
- Testing
- Detection of circulating tumor cells expressing Axl: CTC-AXL(+)
- Where
- France
- Volunteers
- 63 people
- Sponsor
- University Hospital, Montpellier
Breast Cancer, Metastatic, Metastatic Breast Cancer
Stereotactic Ablative Body Radiotherapy (SABR) With Maintenance of Systemic Therapy Versus Physicians' Choice of Systemic Therapy for Oligoprogressive ER-positive, Her-2 Negative Breast Cancer II
The goal of this clinical trial is to assess Stereotactic Ablative Radiotherapy (SABR) as a method to delay a change in systemic therapy in patients with oligoprogressive ER-positive, HER2-negative advanced breast cancer.
- Trial name
- AVATARII (NCT06882499)
- Testing
- Stereotactic Ablative Radiotherapy, Physician's choice of systemic treatment
- Volunteers
- 74 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
Liver Only Metastasis From KRAS Exon 2 Wild Type (Under Protocol 1.0-1.2 Edition) and RAS Wild Type (Under Protocol 2.0 Edition) Colorectal Cancer
Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver Metastases
The purpose of this study is to evaluate efficacy and safety of mFOLFOX6+bevacizumab and mFOLFOX6+cetuximab for liver only metastasis from KRAS Exon 2 wild type (under protocol 1.0-1.2 edition) and RAS wild type (under protocol…
- Trial name
- ATOM (NCT01836653)
- Testing
- Bevacizumab, Cetuximab, L-OHP
- Where
- Japan
- Volunteers
- 122 people
- Sponsor
- EPS Corporation
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.